Pancreatic adenocarcinosarcoma of monoclonal origin: A case report

Table 1 Immunohistochemistry markers used in this study

Marker	Tumor component
	Adenocarcinoma	Sarcoma
Pan-CK	Positive	Positive
CK-7	Positive	Negative
CK-19	Positive	Negative
Vimentin	Negative	Positive
Desmin	Negative	Negative
CD34	Negative	Negative
CD117	Negative	Negative
Actin	Negative	Negative
AFP	Negative	Negative

CK: cytokeratin; AFP: alpha-fetoprotein.

Table 2 Mutation in codon 12 of exon 2 in KRAS

	Ct			∆Ct-2		∆Ct-1
	Non-PNA	KRAS 12	KRAS 13	KRAS 12	KRAS 13	KRAS 12	KRAS 13
The sarcomatous portions of the pancreatic tumor
T1	27.05	29.65	38.00	2.61	10.95	5.35	-2.00
Control	25.22	37.59	39.25	-	-	-	-
Standard Ct	-	35.00	36.00
Result	KRAS codon 12 mutation
The carcinomatous portions of the pancreatic tumor
T2	24.96	27.50	38.00	2.54	13.04	7.50	-2.00
Control	25.22	37.59	39.25	-	-	-	-
Standard Ct	-	35.00	36.00
Result	KRAS codon 12 mutation

A mutation was identified if the ∆Ct-1 ≥ 2.0, meaning the mutated DNA sequences were amplified at least two cycles earlier than wildtype; If 0 ≤ ∆Ct-1 ≤ 2.0, ∆Ct-2 must be ≤ 6; The ∆Ct is the beginning value of sample amplification; The standard Ct designates the value where the wildtype sample began to amplify; ∆Ct-1 = Standard Ct – Sample Ct; and ∆Ct-2 = Sample Ct – Non-PNA Ct. Ct: threshold cycle; PNA: peptide nucleic acid.